Comparing nodal versus bony metastatic spread using tumour phylogenies

S Mangiola; MKH Hong; M Cmero; N Kurganovs; A Ryan; AJ Costello; NM Corcoran; G MacIntyre; CM Hovens

Journal article

Comparing nodal versus bony metastatic spread using tumour phylogenies

S Mangiola, MKH Hong, M Cmero, N Kurganovs, A Ryan, AJ Costello, NM Corcoran, G MacIntyre, CM Hovens

Scientific Reports | NATURE PORTFOLIO | Published : 2016

DOI: 10.1038/srep33918

Download PDF

Abstract

The role of lymph node metastases in distant prostate cancer dissemination and lethality is ill defined. Patients with metastases restricted to lymph nodes have a better prognosis than those with distant metastatic spread, suggesting the possibility of distinct aetiologies. To explore this, we traced patterns of cancer dissemination using tumour phylogenies inferred from genome-wide copy-number profiling of 48 samples across 3 patients with lymph node metastatic disease and 3 patients with osseous metastatic disease. Our results show that metastatic cells in regional lymph nodes originate from evolutionary advanced extraprostatic tumour cells rather than less advanced central tumour cell pop..

View full abstract

University of Melbourne Researchers

Stefano Mangiola Author

Marek Cmero Author

Anthony Costello Author

Niall Corcoran Author

Related Projects (3)

Determining the origin of lethal metastases in multifocal primary prostate cancer

New biomarkers are required to accurately predict lethal prostate cancer from benign, indolent disaese that doesn't require expensive treatm..

TRACKING THE ORIGINS AND DRIVERS OF METASTASIS IN PROSTATE CANCER

Prostate cancer is now the most commonly diagnosed cancer but only 10% of men with it, will die from it. Our current ability to discriminate..

Investigation of the source of new testosterone production in prostate tumours that become resistant to existing hormonal (testosterone lowering and blocking) therapies

Prostate cancer is critically dependent upon continued testosterone stimulation, even when the disease becomes resistant to existing hormona..

Grants

Awarded by National Science Foundation

Funding Acknowledgements

We thank M. Kerger and P. Xibberas for tumour sample collection and patient disease annotation. We thank all members of the CMH laboratory for helpful comments and editing of this manuscript. This work was supported, in part, by NHMRC grants 1047581 and 1104010 to CMH and 1024081 to NMC. The Ovarian Cancer Action [BriTROC project grant: G.M]; The University of Cambridge, Cancer Research UK, Hutchinson Whampoa Limited, CRUK core grant C14303/A17197 (CRUK CI institute core grant, GM).